HIV-infected infants develop broadly neutralizing plasma responses with more rapid kinetics than adults, suggesting the ontogeny of infant responses could better inform a path to achievable vaccine targets. We developed computational methods to reconstruct the developmental lineage of BF520.1, the first example of a HIV-specific broadly neutralizing antibody (bnAb) from an infant. The BF520.1 inferred naïve precursor binds HIV Env and a bnAb evolved within six months of infection and required only 3% mutation. Mutagenesis and structural analyses revealed that for this infant bnAb, substitutions in the kappa chain were critical for activity, particularly in CDRL1. Overall, the developmental pathway of this infant antibody includes features distinct from adult antibodies, including several that may be amenable to better vaccine responses.
Summary
HIV-infected infants develop broadly neutralizing plasma responses with more rapid kinetics than adults, suggesting the ontogeny of infant responses could better inform a path to achievable vaccine targets. We developed computational methods to reconstruct the developmental lineage of BF520.1, the first example of a HIV-specific broadly neutralizing antibody (bnAb) from an infant. The BF520.1 inferred naïve precursor binds HIV Env and a bnAb evolved within six months of infection and required only 3% mutation. Mutagenesis and structural analyses revealed that for this infant bnAb, substitutions in the kappa chain were critical for activity, particularly in CDRL1. Overall, the developmental pathway of this infant antibody includes features distinct from adult antibodies, including several that may be amenable to better vaccine responses.
Considerable efforts are spent on defining evolutionary pathways of broadly neutralizing 1 antibodies (bnAbs) in HIV-1 infection under the premise that these pathways will help guide 2 effective immunization strategies 1 . Particular emphasis has been placed on bnAb epitopes that 3 are common in different individuals 2 , such as the V3-glycan region of HIV-1 envelope (Env) 3 , 4 and much progress has been made toward characterizing the development of V3-glycan bnAbs 5 in adults [4] [5] [6] [7] . While the evolutionary pathway of adult bnAbs have been dissected to inform 6 vaccine approaches 2 , significant challenges remain to be addressed for inducing bnAb 7 responses by vaccination. One such challenge is that most adult bnAbs take years to develop 8 as a result of a complex interplay between viral escape and antibody maturation 2 that often 9 leads to extensive somatic hypermutation (SHM), ranging from ~6-29% (averaging ~18%) for 10 adult-derived V3-glycan bnAbs 4, 6, [8] [9] [10] [11] [12] [13] . Additionally, the inferred germline precursors of a number 11 of bnAbs lack detectable binding to recombinant HIV envelope and thus require the design of 12 germline-targeting immunogens for vaccines 4, 5, 7, 8, 14, 15 . Furthermore, some bnAbs are limited by 13 autoreactivity 6, 8, 16 . 14
Results

28
Ontogeny of the infant-derived bnAb BF520.1 29 Infant BF520 was infected with a clade A HIV virus, detectable at 3.8 months of age, and 30 a broadly-neutralizing V3 glycan-directed monoclonal antibody (mAb) BF520.1 was isolated one 31 year post-infection (pi) 19 at 15 months of age. To infer the ontogeny of this bnAb, we performed 32 next generation sequencing of the infant's B cell repertoire on an available post-infection sample 33 from 6 months pi (9 months of age). We inferred the naïve heavy chain (VH) and light chain 34 (VK) ancestors of the BF520.1 mAb and identified all clonally-related sequences that descended 35 from these ancestors (i.e. the clonal family of the bnAb) using the partis software package [22] [23] [24] , 36 which is more accurate than previous methods but has not been previously applied to deep 37 sequencing bnAb inference. 38
To illustrate where BF520.1 falls within the context of its clonal family, maximum 39 likelihood (ML) phylogenetic trees were inferred for VH and VK clonal families (Fig. 1a,c) . To 40 reconstruct the most probable developmental routes taken by BF520.1 VH and VK sequences 41 during the first six months of infection, we performed Bayesian phylogenetic and ancestral 42 sequence inference analyses for each antibody chain. Importantly, this approach allowed us to 43 rigorously estimate developmental route uncertainty because it accounts for phylogenetic 44 uncertainty by considering many different phylogenies, which ML does not. We computationally 45 validated that Bayesian lineage reconstruction correctly identified ancestral sequences for 46 simulated antibody lineages with similar characteristics to that of BF520.1 97% of the time for 47 ancestral sequences with posterior probability > 0.8, while dnaml and dnapars were less 48 accurate (87% and 89%, respectively) ( Supplementary Fig. 1 ). Therefore, inspired by Gong et 49 al.'s approach for reconstructing influenza evolution 25 , we developed a software pipeline that 50 uses Bayesian phylogenetics 26,27 to reconstruct BF520.1 VH and VK lineages while retaining 51 relative confidences for internal node sequences (Fig. 1b,d) . 52
Using two replicates of NGS data, we selected the most probable routes of development 53 for the BF520.1 heavy and light chains based on Bayesian lineage inference between infection 54 and 6 months pi. We synthesized chosen lineage intermediates for further study: VH 55 intermediates 1-3 (Int1-3VH) and VK intermediates 1-4 (Int1-4VK). Selection of these lineages 56 relied on considering the most confident transitions (Fig 1b,d ; darkest blue arrows) from the 57 naïve sequence to the mature BF520.1 sequence in both NGS replicates. For the heavy chain, 58 both replicates indicated that the G57D substitution occurred first and thus Int1VH included this 59 change. The Y32N amino acid substitution occurred next in both replicates and was therefore 60 incorporated in Int2VH. The M34I and F114L substitutions were inferred in one of the two 61
replicates, but the order was unclear, so both were added to Int3VH. For the kappa chain, both 62
replicates supported L78M as the first mutation, so this substitution was added to create Int1VK. 63
However, there was less agreement between replicates on the chronological order of the 64 substitutions that followed. Both agreed that two substitutions (S30A and S67F) occurred prior 65 to two later substitutions (S28N and T53S), so these steps were incorporated as Int2VK and 66
Int3VK. Finally, the A25T substitution was incorporated into Int4VK because one of the two 67 replicates indicated that this was a possible late substitution. Using this approach, we 68 reconstructed highly probable routes of heavy and light chain antibody development within the 69 first 6 months of HIV infection. 70 71 Fig. 1 we obtained 10,000 independent tree samples from RevBayes and computed the median root-97 to-tip branch length distance for each sequence in the clonal family. Each of the 10 simulated 98 clonal families were obtained using the same simulation parameters. 99 methods against corresponding single ML (Supplementary Fig. 2a ) and Pars phylogenies 127 ( Supplementary Fig. 2c ) to infer BF520.1 intermediates. Interestingly, the VH intermediates 128 inferred from the ML phylogeny included substitutions that were not found in either the naïve or 129 mature mAbs, indicating that they were likely erroneous. The Bayesian lineages also included 130 substitution reversions, but these paths consistently had lower posterior probabilities than paths 131 lacking these artifacts (Fig. 1b,d ). When present, these substitutions decreased neutralizing 132 activity, which is apparent when comparing ML Int3VH and ML Int4VH ( Supplementary Fig. 2a,b) . Fig. 2c,d) . 141
Overall, these data demonstrate increasing heterologous neutralizing activity with affinity 142 maturation and show that the heavy chain CDRH1 Y32N and CDHR2 N52A substitutions are 143 important for the neutralization breadth of BF520.1. 144 (Fig. 3a) than the converse 176 matureVHnaïveVK mAb (KD=8.95nM) (Fig. 3b) . In contrast to the heterologous neutralizing activity 177 seen for the naïveVHmatureVK mAb, the matureVHnaïveVK mAb neutralized only tier 1A SF162 178 variant but not tier 2 viruses (Fig. 3b ). These data suggest that maturation in VK is necessary for 179 BF520.1 heterologous neutralization breadth. 180
To identify which mutations in VK contributed to increased neutralizing activity, VK 181
Bayesian lineage intermediates (Int1-4VK) and subsequent rationally-inferred intermediates (Int5-182 7VK) were paired with the mature VH and tested for cross-clade tier 2 neutralizing activity. 183
Overall, VK lineage intermediates demonstrated increasing breadth with maturation ( Fig. 3c,d) . 184
A dramatic jump in neutralization breadth was demonstrated by Int2VK, which contains CDRL1 185 S30A and FR3 S67F substitutions (Fig. 3c,d ). Although S67F was observed prior to the S30A 186 substitution in the ML and Pars VK lineages, it did not increase neutralization breadth 187 ( Supplementary Fig. 3a-d) , suggesting that the S30A CDRL1 substitution alone enables the 188 observed heterologous neutralization breadth. Further augmentation of potency and breadth 189 was conferred by substitutions observed in Int3VK (CDRL1 S28N and CDRL2 T53S). The T53S 190 substitution was observed prior to S28N in the ML VK lineage and it did not increase breadth 191 but did confer a slight increase in potency. Int4VK (FR1 A25T) had a very modest increase in 192 activity. Importantly, Int5VK (CDRL1 S31Y and CDRL2 G50E) neutralized all viruses that were 193 neutralized by the mature antibody and Int6VK (FR2 L33F) reached potency comparable to 194 BF520.1 (Fig. 3c,d) . Intermediates designated as >M6 pi were rationally inferred. 219
Cross-clade neutralization with limited SHM in paired intermediates 220
To define the minimal combination of changes in VH and VK that are needed for 221 breadth, intermediates were paired together using percentage SHM to assign probable pairings. 222
Tier 1A neutralizing activity was observed following just two amino acid substitutions in VH 223 (Int2VH) and three in VK (Int2Vk) (Fig. 4) with the additions of the VH Y32N and VK S30A being 224 important for the neutralizing activity. Cross-clade heterologous neutralization was achieved 225 with the addition of the VH M34I and VK S28N in the Int3VHInt3Vk mAb, which had a total of four 226 VH and five VK amino acid substitutions or 1.3% and 1.8% SHM at the nucleotide level in VH 227 and VK, respectively. Int4VH paired with Int4VK neutralized the majority of the viruses (9/13; 69%) 228 that are neutralized by mature BF520.1 with only 1.8 VH and 2.1% VK SHM. Further increased 229 neutralization was conferred by single additional substitutions in both VH and VK: N52A (Int4VH) 230 and A25T (Int4VK). The breadth of BF520.1 was reached with 1.8% VH and 3.4% VK SHM 231 (2.5% overall SHM) for Int4VHInt5VK. Finally, the Int5VHInt6VK mAb reached the breadth and 232 potency of mature BF520.1 with only 2.4% VH and 3.7% VK SHM (3.0% overall SHM) (Fig. 4) . 233
Similar observations were made using the ML (Supplementary Fig. 4a ) and Pars 234 ( Supplementary Fig. 4b Cryo-EM structure of the BG505.SOSIP.664 trimer in complex with BF520.1 Fab 248
Single particle cryo-electron microscopy was used to gain insight into the interaction of 249 BF520.1 Fab and BG505.SOSIP.664 trimer, which is a clade A transmitted envelope variant 250 from a Kenyan infant who was in the same cohort as BF520 32,33 . The resulting 4.8Å map (Fig. 5  251 and Supplementary Fig. 5 ) revealed features consistent with the resolution estimate including 252 helices, beta-sheet structure as well as bulky densities for glycans that protrude from 253 glycosylation sites, including N332 and N301, which are critical features for BF520.1 activity [34] [35] [36] [37] 254 ( Supplementary Fig. 5e ). 255
The positioning of the CDRH loops in our structural model indicates that they make 256 multiple contacts with both protein and N-linked glycans (Fig. 1b) . The CDRH1 loop is in close 257 proximity to the base of the gp120 V3-loop, with N32 oriented towards the conserved GDIR 258 sequence, consistent with increased neutralization observed when asparagine is introduced at 259 position 32 on the CDRH1 loop (Y32N substitution). Adjacent residues of CDRH1 as well as the 260 CDRH2 loop are located proximal to the N301 glycan. It is unclear if residue 52 (N52A 261 substitution) in CDRH2 mediates direct contact between either the GDIR sequence or N301 262 glycan; however, it is plausible that substitution for alanine could influence loop positioning such 263 that residues H54 and S55 would interact with the N301 glycan. The relative orientation of the 264 CDRH3 loop suggests it may interact with the V3 GDIR sequence as well as the N332 glycan, 265 though given variability in CDRH3 positioning between homology models, the contacts are less 266 certain for this loop. 267
The structure of the Env trimer in complex with BF520.1 supports a role for the BF520.1 268 VK in neutralization through extensive contacts between the CDRL1 loop and the N332 glycan. 269
Based upon the BF520.1 homology model, N28, A30, and Y31, which were implicated in nAb 270 breadth, are positioned directly adjacent to the N332 glycan (Fig. 5c ), although we cannot 271 unambiguously identify the position of specific residues. L33F and G50E mutations contributed 272 to increased potency, but from the structure it is unclear whether these residues could directly 273 contact the N332 glycan or protein surface 38,39 ; they may instead alter local paratope structure in 274 a more indirect fashion. The position of CDRL3 loop suggests it likely does not interact with the 275 BG505 trimer or key glycans, which may explain why it does not contain mutations that 276 contribute to BF520.1 breadth. 277 Figure 5g) . b, Expanded view of the VH domain and gp120. Shown are 286 the conserved gp120 GDIR sequence (purple), glycans N332 and N301, and CDRH loops 287 (green). Mutations that confer potent neutralization (red) are indicated. it weakly bound to BG505.SOSIP.664 trimer (Fig. 6a ) and this binding was dependent on 309 increasing mAb concentration (Fig. 6b) . Qualitatively, we observed increased binding with 310 affinity maturation (Fig. 6a) SOSIP trimer by Int2VH2VK, Int3VH3VK, and Int3VH4VK, these intermediates were not able to 314 neutralize the BG505 pseudovirus (Fig. 4 and 6a) . These data indicate that the BF520.1 naïve 315 mAb had the potential to recognize HIV Env. 316
Our approach to inferring the naïve ancestor using replicate sequence data differed from 317 previous studies, which only used single replicates of NGS data 6, 29, 30 . To compare the two 318 methods, we also inferred the BF520.1 naïve ancestor using just the first replicate of antibody 319 sequence data. This approach resulted in uncertainty in the naïve nucleotide sequences at 320 three positions ( Supplementary Fig. 6a,b) while there was not uncertainty using replicate 321 datasets. When tested, none of the alternative inferred naïve mAbs demonstrated neutralization 322 ( Supplementary Fig. 6c ), nor did they bind trimer ( Supplementary Fig. 6d ), which contrasts the 323 ability of the more probable replicate-inferred naïve mAb. We also found differences in the 324 autoreactivity of the inferred naïve mAbs: single dataset-inferred mAbs demonstrated weak 325 autoreactivity ( Supplementary Fig. 6e Fig. 7) . 356
Likewise, the earliest paired intermediates failed to neutralize the M6 variants. Lineage member 357
Int4VH4VK neutralized BF520.M6P.I1 with lower potency compared to BF520.1 (5.8 vs. The complex developmental pathways of bnAbs in HIV-infected adults have been 374 carefully examined to guide immunogen design targeting key precursors in antibody 375 evolutionary pathways 2 . In many cases, this approach is complicated by the observation that the 376 inferred naïve progenitor of the bnAb does not bind HIV Env, presenting challenges to 377 stimulating the lineage 15 . Taking advantage of the rapid development of HIV bnAb responses in 378 infants, here we discovered an evolutionary pathway that starts with a naïve antibody that is 379 capable of binding HIV Env trimer and requires as little as 3% SHM to achieve the full cross 380 clade breadth of this lineage. Remarkably, this antibody lineage relies on changes in both the 381 heavy and light chains, mostly outside of the CDRH3, to develop HIV specificity and breadth. 382
Thus, this antibody developmental pathway allows for two key aspects of vaccine design that 383 were stumbling blocks for many adult bnAbs pathways: the HIV antigen can engage the naïve B 384 cell and a level of SHM that is easily within reach by vaccination 40 . 385 V3-glycan targeting bnAbs are of high interest because they are common and not 386 restricted by certain germline genes 4,6,8,10,12,19 . BF520.1 is of particular interest because it 387 developed more rapidly than adult V3-bnAbs and achieved broad and potent capability with as 388 little as 3.0% SHM (2.4% VH and 3.7%VK SHM). Other known adult V3-glycan bnAbs required 389 rare mutation events to occur 4,7 and/or higher levels of SHM 6 compared to BF520.1 41 . The 390 highly impactful N52A substitution in the BF520.1 heavy chain required one nucleotide mutation 391 in an AID hotspot site and one mutation in a neutral site, but the improbability of these mutations 392
was not a barrier to rapid bnAb development in this infant. This indicates that vaccines may be 393 able to stimulate similar mutations in reasonable timeframes. 394
Interestingly, mutations important for increasing BF520.1 functional activity were 395 primarily found in the heavy chain CDRH2 and light chain CDRL1, with little-to-no contribution 396 from the CDRH3 and CDRL3. The Cryo-EM structural model indicated that CDRH2 and CDRL1 397 residues appear to contribute to the BF520.1 paratope by mediating contacts with the 398 conserved V3-glycan site, namely the archetypal features of V3-targeting bnAbs: GDIR 399 sequence and glycans at position 301 and 332 42 . In contrast to the position of CDRL3, located 400 too distant to make meaningful contacts with the trimer, the structure suggests that CDRH3 may 401 interact with both the V3 GDIR sequence and N332 glycan; however, the lack of substitutions in 402 the loop during SHM suggests a likely minor role for CDRH3 in BF520.1's maturation. This 403 contrasts many HIV bnAbs where major determinants of breadth reside in the CDR3 regions, 404 particularly in VH 44 . 405 We identified that maturation in the BF520. The observation that the earlier intermediates are HIV-specific but do not neutralize the 422 autologous virus suggests that the virus at ~2 months pi may have escaped neutralization by 423 the early lineage. We do not know whether the naïve or early lineage mAbs were able to bind 424 autologous viruses at the time of infection or at ~2 months pi. naïve sequences that impacted the overall characterization of our antibody lineage. We are 438 confident in our BF520.1 naïve inference for three reasons: 1) we used the entire clonal family 439 to infer the naïve sequence along with more accurate clonal family clustering, which together 440 increase confidence especially within the CDR3 22,23 , 2) we used per-sample germline 441 inference 24 , which mitigates gene assignment errors and expands our ability to accurately infer 442 antibody ontogenies in non-European subjects whose antibody gene usage patterns are less 443 well documented, and 3) BF520.1 had very low SHM compared to other bnAbs, which alleviated 444 the difficulty of naïve inference due to a reduced expected number of incorrect bases. Notably, 445 our most probable replicate-inferred naïve mAb measurably bound HIV and did not demonstrate 446 autoreactivity. Conversely, the single-dataset inferred naïve mAbs that contained uncertainties 447 displayed autoreactivity, which is misleading because this is indeed a feature of many adult 448 bnAbs 16 and some V3-glycan bnAbs 6, 8 . These discrepancies highlight the potential imprecision 449 of naïve antibody inference due to insufficient quality or depth of sequencing data and suggest 450 that our newer approaches designed specifically for antibody lineage analysis should be used. 451 The finding that infants develop broad and potent HIV bnAb responses has raised the 452 question of whether HIV vaccine efforts should focus on infants 20 
